Pentadeca Arginate
From PeptidePlaza, the free peptide reference · Entry #041 · Recovery · Hand-curated entry · Editorial standards
Pentadeca Arginate (also known as PDA, BPC-157 Arginate, Pentadecapeptide arginate) is a recovery research peptide. The same fifteen amino acids as BPC-157, paired with an arginine counterion instead of acetate. Marketed as a successor compound; chemically, it is a salt form.
Pentadeca Arginate (PDA) is BPC-157 formulated as an arginate salt rather than the conventional acetate salt. The peptide sequence is identical — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, the same partial sequence of human gastric juice protein BPC. The only difference is the counterion. PDA emerged commercially after the FDA classified BPC-157 as a Category 2 bulk drug substance, prohibiting its use in 503A and 503B compounding, and the arginate form was promoted with claims of dramatically superior stability — a figure of "1,000× more stable at pH 3.0" circulates widely in marketing material but has never appeared in a peer-reviewed publication. As of 2026, no peer-reviewed study has investigated pentadeca arginate as a distinct molecule: its entire evidence base is inherited from BPC-157, which itself rests on extensive rodent data (angiogenesis via VEGFR2, nitric oxide system modulation, tendon fibroblast migration, gut and vascular protection) and a single uncontrolled 12-patient case series in humans — a 2025 systematic review screened 544 papers and found nothing more. Arginine as a counterion is plausibly favourable for solubility and, as a nitric oxide precursor, is theoretically synergistic with BPC-157's NO-dependent mechanisms, but that is reasoning, not evidence.
1 Mechanism of action
Identical to BPC-157: upregulates VEGFR2 and the FAK-paxillin pathway to drive angiogenesis, modulates the nitric oxide system, promotes fibroblast and tendon-cell migration, and influences growth hormone receptor expression in tendon fibroblasts. The arginate counterion may improve aqueous solubility and contribute arginine as an NO precursor.
Primary targets: VEGFR2 · Nitric oxide synthase pathways · GH receptor (tendon fibroblasts)
2 Reported effects
Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.
2.1 Reported benefits
- Inherits BPC-157's extensive preclinical tendon, ligament and gut healing data
- Arginate counterion improves aqueous solubility
- Arginine as a nitric oxide precursor is theoretically complementary to the NO-dependent mechanism
- Angiogenic activity via VEGFR2 upregulation in animal models
- Cytoprotective effects across gastrointestinal, vascular and musculoskeletal rodent models
2.2 Side effects
- No human safety trial data for the arginate form
- Injection site reactions reported anecdotally
- Theoretical concern: angiogenesis promotion in the presence of occult malignancy
- Unknown effects of the arginine load with high-dose chronic use
3 Chemical and physical properties
| Molar mass | 1419.5 g/mol (peptide free base) |
|---|---|
| Purity (typical) | >99% |
| Half-life | Short systemically (minutes to ~1 hour); local tissue effects outlast plasma presence |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
| Receptors / targets | VEGFR2, Nitric oxide synthase pathways, GH receptor (tendon fibroblasts) |
3.1 Amino acid sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (arginate salt)
4 Research dosages
No validated protocol. Research use commonly mirrors BPC-157 conventions (250–500 μg/day SC), based on rodent extrapolation rather than human data.
5 Research studies (7)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
HSS Journal (2025) · Systematic Review · 544 papers screenedSystematic review screening the published literature for human evidence supporting BPC-157 in musculoskeletal injury.Key finding: Despite extensive rodent data, human evidence is limited to a single uncontrolled case series — no randomised human trial exists. - Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery (2025) · ReviewBackground: Body protection compound-157 (BPC-157) is a naturally occurring gastric peptide that promotes mucosal integrity and homeostasis. - Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.
Current reviews in musculoskeletal medicine (2025) · ReviewOF REVIEW: This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. - Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle.
Biomedicines (2022) · ReviewFirst, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached... - Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Frontiers in pharmacology (2021) · ReviewSignificance: The antiulcer peptide, stable gastric pentadecapeptide BPC 157 (previously employed in ulcerative colitis and multiple sclerosis trials, no reported toxicity (LD1 not achieved)), is reviewed,... - Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy.
Current pharmaceutical design (2020) · ReviewThis review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. - Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Cell and tissue research (2019) · ReviewThere is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders.
6 Safety and risk profile
6.1 Regulatory status
Pentadeca Arginate is currently classified as Not approved. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
Safety score: 55/100 — moderate concern. Derived from clinical data volume, known risks and regulatory status.
6.2 Contraindications
Conditions and populations in which use is contraindicated:
- Known or suspected malignancy (angiogenic mechanism)
- Pregnancy or lactation
- Active proliferative retinopathy (theoretical, angiogenesis-related)
- Known hypersensitivity
6.3 Drug interactions
| Drug or class | Interaction | Risk |
|---|---|---|
| Anti-angiogenic therapies (bevacizumab, TKIs) | Directly opposing mechanisms — VEGFR2 upregulation counteracts anti-angiogenic treatment. | High |
| Nitric oxide donors / PDE5 inhibitors | Additive NO-pathway effects; theoretical blood pressure interaction. | Moderate |
| Corticosteroids | Steroids impair the healing processes this peptide is used to support. | Low |
6.4 Long-term risks
- No long-term human data for either the acetate or arginate form
- Theoretical tumour promotion via sustained angiogenic signalling
- Unknown immunogenicity with chronic administration
6.5 Research best practices
- Store lyophilised at −20 °C, protected from light and moisture
- Reconstitute with bacteriostatic water; refrigerate at 2–8 °C
- Demand a COA with HPLC purity and mass spec identity — counterion substitution is easy to misrepresent
- Do not assume PDA-specific data exists; evaluate it on BPC-157 evidence
7 Frequently asked questions
- Is PDA actually different from BPC-157?
- Chemically, only in its counterion — the 15-amino-acid sequence is identical. Marketing frames PDA as an improved successor; the peer-reviewed literature contains no study of pentadeca arginate as a distinct molecule, so any claimed superiority is unverified.
- Where does the "1,000× more stable" claim come from?
- Compounding pharmacy marketing material. It refers to stability at pH 3.0 and has not been published in any peer-reviewed journal as of 2026. Treat it as a vendor claim, not a research finding.
- Why did PDA appear on the market when it did?
- The FDA placed BPC-157 in Category 2 of its bulk drug substances list, barring it from 503A and 503B compounding. PDA was positioned as a distinct compound following that decision. Its regulatory status is not settled and it is not FDA-approved.
8 References
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. PubMed (2025). Vasireddi N, et al.. View source
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PubMed (2025). McGuire FP, et al.. View source
- Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle. PubMed (2022). Staresinic M, et al.. View source
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. PubMed (2021). Seiwerth S, et al.. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Pentadeca Arginate.
Shares promotes and angiogenesis pharmacology
A 15-amino acid cytoprotective peptide derived from human gastric juice. Widely researched for wound healing, tendon repair, and GI protection across hundreds of animal studies.
Shares expression and promotes pharmacology
The only human cathelicidin host-defense peptide. Kills bacteria, modulates inflammation, promotes wound healing, and is being studied for infections, sepsis, and tissue repair.
Shares fibroblasts and upregulates pharmacology
A naturally occurring tripeptide-copper complex found in human plasma, saliva, and urine. Plasma levels decline sharply with age. Extensively studied for collagen induction, skin remodeling, and gene expression regulation.
Shares migration and promotes pharmacology
A synthetic fragment of Thymosin Beta-4, a ubiquitous actin-sequestering protein. Research focuses on promoting tissue repair, reducing inflammation, and supporting angiogenesis in cardiac and skeletal muscle models.
Shares modulates and upregulates pharmacology
A synthetic analog of the endogenous tetrapeptide Tuftsin. Developed by the Russian Institute of Molecular Genetics. Studied for anxiolytic, nootropic, and immunomodulatory effects without sedation or dependence.
Shares upregulates and promotes pharmacology
A 28-amino acid thymic peptide that modulates T-cell function and cytokine balance. Studied clinically for chronic hepatitis B, sepsis, and vaccine response augmentation for over 30 years.